| Literature DB >> 36185596 |
Shijun Wang1, Shu Zhu1, Ziqi Kang1, Yidan Chen2, Xiancheng Liu2, Zixin Deng1, Kun Hu1, Guixue Wang2,3, Yuchan Zhang1, Guangchao Zang1,3.
Abstract
The potential-resolved strategy has gradually demonstrated its distinct values in electrochemiluminescence (ECL) bio-sensing due to its superior characteristics, such as low instrument requirement, short assay time, and improved sample throughput, in conjunction with spatial- and spectrum-resolved techniques. It has recently been widely generalized into versatile multiple-signal ECL analytic platforms, especially in ratiometric and multiplex ECL sensors, in accordance with some specific principles. Furthermore, luminophore pairs with potential- and wavelength-resolved properties have been utilized to visualize biosensors that display multiple colors depending on analyte concentration. However, only a few comprehensive reports on the principles, construction, and application of various ECL sensors in potential-resolved schemes have been published. This review aims to recount the potential-resolved strategy applying to (a) ratiometric ECL sensors, (b) multiplex ECL sensors, and (c) multicolor ECL sensors and to discuss the distinctions and connections among the application principles of these strategies. Finally, the future prospects of ECL-based potential-resolved analysis are explored. © The author(s).Entities:
Keywords: electrochemiluminescence; multicolor electrochemiluminescence sensors; multiplex electrochemiluminescence sensors; potential-resolved strategy; ratiometric electrochemiluminescence sensors
Mesh:
Year: 2022 PMID: 36185596 PMCID: PMC9516240 DOI: 10.7150/thno.74308
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.600
Summary of the partial reports on potential-resolved ratiometric ECL analyses based on the ECL-RET strategy or/and intermediate reagent strategy. Unavailable measurements are represented by "-"
| Sensing strategies | Donor | Acceptor | Linear range | LOD | Target | Ref. |
|---|---|---|---|---|---|---|
| RET/intermediate reagent | CdS-CNFs | Luminol-AuNPs | 1.0 × 10-16-1.0 × 10-15 g/mL | 3.3 × 10-14 g/mL | Carcinoembryonic antigen |
|
| CdS NCs | Luminol-AuNPs | - | 5.0 × 10-13 g/mL | Thrombin |
| |
| CdS QDs | Au@luminol | 1.0 × 10-5-1.0 × 10-2 M | 2.8 × 10-6 M | Mg2+ |
| |
| g-CdTe QDs | TAEA-Ru | 1.0 × 10-14-1.0 × 10-9 M | 2.9 × 10-12 M | DA |
| |
| CdSe/ZnS QDs | Luminol | 5.0 × 10-10-5.0 × 10-7 g/mL | - | Prostate specific antigen |
| |
| g-C3N4 NSs | Ag-PAMAM-luminol | 2.0 × 102-9.0 × 103 cells/mL | 1.5 × 102 cells/mL | HL-60 cancer cells |
| |
| CdSe/ZnS | Au-Luminol NPs | 5.0 × 10-16-5.0 × 10-13 M | 1.2 × 10-16 M | Target DNA |
| |
| CdTe/CdS/ZnS QDs | DNA2/H/Au | 5.0 × 10-12-1.0 × 10-8 M | 1.2 × 10-13 M | AFB1 |
| |
| GQDs | Luminol-AuNPs | 1.0 × 10-2-1.0 × 10 U/mL | 5.0 × 10-13 U/mL | Protein kinase A |
| |
| CdS NCs | Luminol | 5.0 × 10-16-1.0 × 10-14 M | 2.4 × 10-16 M | Duplex-specific nuclease |
| |
| RET | O2/S2O82- | PTC-NH2 | 1.0 × 10-12- 1.0 × 10-7 M | 3.5 × 10-13 M | Pb2+ |
|
| CdS QDs | Luminol | 1.0 × 10-11- 2.0 × 10-6 M | 3.0 × 10-12 M | Pb2+ |
| |
| MPA-CdS:Eu NCs | Luminol | 1.0-3.0 × 10 U/mL | 7.0 × 10-2 U/mL | Human methyltransferase |
| |
| CdSe QDs | Luminol | 5.0 × 10-6-1.0 × 10-4 M | 5.0 × 10-6 M | H2O2 |
| |
| CdTe@CdS QDs | Luminol | 1.0 × 10-7-5.0 × 10-13 g/mL | 4.2 × 10-15 g/mL | Thrombin |
| |
| CdS QDs | Au-Luminol | - | 1.3 × 10-13 g/mL | Carcinoembryonic antigen |
| |
| K2S2O8 | Fluoroboron dipyrrole | 1.0 × 10-13-8.5 × 10-7g/mL | 4.2 × 10-14 g/mL | Lactoferrin |
| |
| HCNS | CPB | 1.0 × 103-3.2 × 105 cells/ mL | 3.2 × 102 cells/ mL | MCF-7 cells and CD44 receptors |
| |
| g-C3N4 | PANI/ABEI | 1.0 × 10-13-4.0 × 10-11 g/mL | 2.3 × 10-14 g/mL | CT |
| |
| CdS NCs | Luminol | 5.0 × 10-15-1.0 × 10-12M | 1.7 × 10-15M | mp53 oncogene |
| |
| Ru-Lu JPs | FAM/Cy5 | 1.0 × 10-14-1.0 × 10-8M | 8.7 × 10-15 /1.2 × 10-15 M | miRNA-21/miRNA-155 |
| |
| SnS2 QDs@Eu MOFs | L-Au-Pt NRs | 1.0 × 10-11-1.0 × 10-7M | 3.2 × 10-13 M | KAN |
|
Figure 1Schematic of the potential resolved ECL-RET biosensors based on (A) the ECL-RET system with luminophores with high color purity and facile band controllability. Adapted with permission from 40, copyright 2020 American Chemical Society; (B) universal enhancer or quencher. Adapted with permission from 51, copyright 2018 Elsevier B.V.; and (C) signal regulation materials. Adapted with permission from 55, copyright 2016 Elsevier B.V.
Figure 2Schematic of potential-resolved competition-strategy sensors with (A) H2O2 as the co-reactant. Adapted with permission from 62, copyright 2020 Springer; and (B) dissolved O2 as the co-reactant. Adapted with permission from 65, copyright 2020 American Chemical Society. (C) Steric hindrance strategy. Adapted with permission from 69, copyright 2019 American Chemical Society. (D) Immune competition mechanism. Adapted with permission from 71, copyright 2016 Elsevier B.V.
Figure 3Schematic of the potential-resolve enzymatic strategy sensors based on the reverse variation of the substrate O2 and H2O2 in (A) the AChE-ChOx enzyme system. Adapted with permission from 75, copyright 2017 American Chemical Society; single H2O2 substrate as the bifunctional moderator in (B) the glucose oxidase system. Adapted with permission from 74, copyright 2020 Elsevier B.V.; and (C) the AChE system. Adapted with permission from 81. Copyright 2021 American Chemical Society.
Figure 4Schematic of single luminophore ratiometric ECL sensors based on dual co-reactants. (A) G-C3N4 and Au-g-C3N4 as the co-reactants of Ru(bpy)32+ for Hg2+ detection. Adapted with permission from 84, copyright 2020 Royal Chemical Society. (B) K2S2O8 and TEA as the co-reactants of porous g-C3N4 NSs for AFP detection. Adapted with permission from 53, copyright 2020 Royal Chemical Society. Single-luminophore ratiometric ECL sensors based on (C) C-dots as the single co-reactant of Ru(bpy)32+ for the determination of the antibiotic TC. Adapted with permission from 87, copyright 2019 Springer.
Figure 5Schematic of the internal standard ratiometric ECL sensor with the physically separated double disk electrode (WE1 and WE2) in (A) a dual-disk inner reference ratiometry system. Adapted with permission from 90, copyright 2020 Royal Chemical Society; (B) a DDCE label-free system. Adapted with permission from 88, copyright 2017 Elsevier B.V. Schematic of the internal standard ratiometric ECL sensor with the physically separated double disk electrode (WE1 and WE2) with single electrode assembled with an internal reference signal probe and working signal probe in (C) a ratiometric antifouling ECL biosensor based on PAMAM-CIZS/ZnS QDs. Adapted with permission from 91, copyright 2020 Elsevier B.V.; and (D) with photothermal amplification strategies. Adapted with permission from 32, copyright 2019 Elsevier B.V.
Figure 6Schematic of sensors for simultaneous multimarker detection based on bilateral anodic-and-cathodic-potential luminescence with (A) L012 and g-C3N4 as the luminophore pairs for the in situ detection of apoptosis factors. Adapted with permission from 26, copyright 2019 American Chemical Society. (B) Luminol and g-C3N4 as the signal probe. Adapted with permission from 101, copyright 2021 Elsevier B.V. Biosensors based on unilateral low-potential luminescence with (C) the low-potential cathode luminophore PDI and co-reactant K2S2O8. Adapted with permission from 114, copyright 2019 American Chemical Society; (D) homogenous luminophores GSH-CdTe QDs and DMSA-CdTe QDs sharing the co-reactant H2O2. Adapted with permission from 115, copyright 2021 Elsevier B.V.; and (E) CIS@ZnS NCs emitting at the ultralow potential of 0.30 V and (Ru(bpy)2(dcbpy))2+ as luminophores. Adapted with permission from 16, copyright 2021 Elsevier B.V.
Figure 7Schematic of anti-cross-talk multidetection sensors based on spatial-resolved strategy with (A) an ITO electrode with three spatially resolved regions for the detection of three biomarkers. Adapted with permission from 116, copyright 2017 American Chemical Society; (B) excessive DBAE. Adapted with permission from 117, copyright 2017 Elsevier B.V.; (C) a novel double working electrode aptamer sensor array on a SPCE. Adapted with permission from 118, copyright 2015 Elsevier B.V.; and the concentration-controlled strategy with (D) the high concentration of luminol. Adapted with permission from 119, copyright 2014 American Chemical Society.
Figure 8Schematic of biosensors with real-time and on-spot detection based on (A) a battery-based microfluidic paper. Adapted with permission from 122, copyright 2012 Royal Chemistry Society. (B) Automatically toggled switch. Adapted with permission from 123, copyright 2013 Elsevier B.V.
Figure 9Schematic of the application of the PRMCECL strategy in (A) MIA by using several self-synthesized concomitant metal complexes with expanded spectral coverage. Adapted with permission from 134, copyright 2018 American Chemical Society. (B) Immunosensor visualization by regulating the interfacial potential (Δϕa) at the poles of BPE. Adapted with permission from 183, copyright 2017 American Chemical Society. (C) Ratiometric biosensor based on the PRMCECL nanoluminophore CdSQDs@MOF-5. Adapted with permission from 141, copyright 2020 American Chemical Society.
Summary of the partial reports on potential-resolved ratiometric ECL analysis based on the competition strategy. Unavailable measurements are represented by "-"
| Competition strategy | Pairs of luminophores | Linear range | LOD | Target | Ref. |
|---|---|---|---|---|---|
| H2O2 | LuAuNPs/AuNPs@CNNS | 1.0 × 102-1.0 × 106 cells/mL | 20 cells/mL | Circulating tumor cells and cell-surface glycans |
|
| O2 | Zinc tetrakis [carboxyphenyl]-porphyrin/luminol | 2.0 × 10-4-10 U /mL | 6.5 × 10-5 U/mL | PNK |
|
| CdTe QDs/ABEI | 1.0 × 10-13-1.0 × 10-8 g/mL | 3.0 × 10-14 g/mL | Concanavalin A |
| |
| DBAE/lucigenin | 1.0 × 10-14-1.0 × 10-8 g/ml | 3.3 × 10-15 g/mL | Human epididymis protein 4 |
| |
| H2O2 | CdS QDs/luminol | 1.0 × 10-12-1.0 × 10-10 g/ mL | 6.2 × 10-13 g/mL | Carcinoembryonic antigen A |
|
| ABEI/g-C3N4 | 1.0 × 10-13-1.0 × 10-8 g/mL | 3.3 × 10-14 g/mL | Zearalenone |
| |
| Steric hindrance | TiO2-Ru(bpy)32+ NPs/PEI-CdS QDs | 1.0 × 10-9-1.0 × 10-4 M | 1.7 × 10-11 M | SA |
|
| nGO@TiO2NLPs/K2S2O8 | 1.0 × 10-13- 1.0 × 10-10 M | 4.0 × 10-14 M | cTnI |
| |
| Au@CDs NFs/Au@luminol NPs | 1.0 × 10-15-1.0 × 10-11 M | 3.4 × 10-16 M | p53 DNA |
| |
| Competitive immunoreaction | Luminol/CS-AgI | 1.0 × 10-15-2.0 × 10-8 g/mL | 1.0 × 10-15 g/mL | AFP |
|
| H2O2 | Ir NRs/CdS QDs | 5.0 × 10-12-5.0 × 10-8 M | 1.67 × 10-12 M | EP |
|
| O2 | Luminol/Cu-TCPP [Zn] | 5.0 × 10-3-5.0 U/mL | 3.7 × 10-3 U/mL | Protein kinase A |
|
Summary of the partial reports on potential-resolved ratiometric ECL analysis based on enzymes. Unavailable measurements are represented by "-"
| Enzyme | Pairs of luminophores | Linear range | LOD | Target | Ref. |
|---|---|---|---|---|---|
| AChE | rGO-CdTe QDs/PFO dots | 5.0 × 10-13-1.0 × 10-8 M | 1.25 × 10-13 M | OPs |
|
| c-PFBT NPs/L-CdS QDs | 5.0 × 10-13-5.0 × 10-7 M. | 1.25 × 10-13 M | EP |
| |
| XOD | rGO-CdTe QDs]/luminol | 2.0 × 10-11 -2.0 × 10-3 M | 7.0 × 10-12 M | Hx |
|
| HRP | ABEI/GSH | 1.0 × 10-13 -1.0 × 10-12 g/mL | 3.3 × 10-14 g/mL | ZEN |
|
| CS-AgI | Luminol/K2S2O8/CS-AgI | 1.0 × 10-15-2.0 × 10-8 g/mL | 1.0 × 10-15 g/mL | AFP |
|
| GOx | PFO NPs | 5.0 × 10-17-1.0 × 10-10 M | 1.7 × 10-17 M | miRNA-155 |
|
Summary of the partial reports on potential-resolved ratiometric ECL analysis based on single luminophores. Unavailable measurements are represented by "-"
| Luminophor | Co-reactant | Linear range | LOD | Target | Ref. |
|---|---|---|---|---|---|
| Ru(bpy)32+ | Au-g-C3N4 NSs | 5.0 × 10-10-5.0 × 10-7 M | 2.0 × 10-10 M | Hg2+ |
|
| NGQDs | O2·-/HO2- | 1.0 × 10-3-7.0 × 10-2 M | 2.0 × 10-4 M | Co2+ |
|
| g-C3N4 | K2S2O8/TEA | 3.0 × 10-16-1.0 × 10-11 g/mL | 1.0 × 10-16 g/mL | AFP |
|
| Ru(bpy)32+ | C-dots | 1.0 × 10-9-1.0 × 10-4 M | 4.7 × 10-10 M | TC |
|
Summary of the partial reports on potential-resolved ratiometric ECL analysis based on the internal standard strategy. Unavailable measurements are represented by "-"
| Luminophor | Tag | Linear range | LOD | Target | Ref. |
|---|---|---|---|---|---|
|
| |||||
| L-AuNPs/CdS NWs | cTnI-rGO-AuNPs-CAT | 5.0 × 10-13-1.0 × 10-7 g/mL | 1.0 × 10-13 g/mL | cTnI |
|
| L-AuNPs/CdS QDs | CA | 1.0 × 10-10-1.2 × 10-7M | 3.0 × 10-11 M | CAP |
|
|
| |||||
| Substrate/internal reference | Label emitter | Linear range | LOD | Target | Ref. |
| Luminol | CdTe QDS | 1.0 × 102-6.5 × 103 cell/mL | 80 cell/mL | MCF-7 cells |
|
| Au@Luminol | CIZS/ZnS QDs | 1.0 × 10-14-1.0 × 10-9 M | 1.82 × 10-15 M | Thrombin |
|
| g-C3N4 | Pdots | 1.0 × 10-14-1.0 × 10-8 g/mL | 3.3 × 10-15 g/mL | Human epididymis protein 4 |
|
Summary of partial reports on potential-resolved multiplex analysis by ECL technology. Unavailable measurements are represented by "-"
| ECL probe & onset potential | Target | LOD | Linear range | Ref. | |
|---|---|---|---|---|---|
|
| |||||
| 1 | CdTe@CdS QDs; -1.12 V | AFP | 1.0 × 10-16 g/mL | 2.5 × 10-16-2.0 × 10-11 g/mL |
|
| Luminol; +0.6 V | CEA | 1.0 × 10-16 g/mL | 2.5 × 10-16-2.0 × 10-11 g/mL | ||
| 2 | CdS QDs; -1.15 V | MG | 3.0 × 10-11 M | 1.0 × 10-10 -1.0 × 10-7 M |
|
| L-AuNPs; +0.6 V | CAP | 7.0 × 10-11 M | 2.0 × 10-10 -1.5 × 10-7 M | ||
| 3 | Ru-NH2; 1.25 V | CA125 | 4.0 × 10-4 U/mL | 0.001-100 U/mL |
|
| AuNPs/g-C3N4; -1.3 V | SCCA | 3.3 × 10-13 g/mL | 1.0 × 10-12-1.0 × 10-7 g/mL | ||
| 4 | AuNPs/luminol; +0.6 V | CEA | - | 3.3 × 10-9-1.6 × 10-8 g |
|
| Ru(bpy)32+; -1.0V | AFP | - | 2.0 × 10-10 -1.1 × 10-9 g | ||
| 5 | Luminol; 0.6 V | Acetamiprid | 1.5 × 10-14 M | 1.0 × 10-10 -1.0 × 10-13 M |
|
| g-C3N4; -1.5 V | Malathion | 1.8 × 10-14 M | 1.0 × 10-10 -1.0 × 10-13 M | ||
| 6 | DMSA-CdTe QDs; -0.89 V | AFP | 1.0 × 10-12 g/mL | 1.0 × 10-12-2.0 × 10-8 g/mL |
|
| TiO2-GSH-CdTe QDs; -1.25 V | AFP-L3 | 3.2 × 10-12 g/mL | 3.2 × 10-12-3.2 × 10-8 g/mL | ||
| 7 | g-C3N4@AuNPs; -1.4 V | miRNA-141 | 3.0 × 10-16 M | 1.0 × 10-15 -1.0 × 10-11 M |
|
| Ru-MOF;+1.5 V | miRNA-21 | 3.0 × 10-16 M | 1.0 × 10-15-1.0 × 10-11 M | ||
| 8 | AuPNs/PDI; -0.6 V | CEA | 7.3 × 10-14 g/mL | 1.0 × 10-13g/mL-1.0 × 10-9 g/mL |
|
| AuPNs/luminol; +0.6 V | AFP | 5.6 × 10-14 g/mL | 1.0 × 10-13g/mL-1.0 × 10-9 g/mL | ||
| 9 | Luminol; +0.6 V | IFN-γ | 1.6 × 10-12 g/mL | 1.6 × 10-12-2.0 × 10-10 g/mL |
|
| Carbon QDs; -1.8 V | TNF-α | 1.6 × 10-12 g/mL | 1.6 × 10-12-2.0 × 10-10 g/mL | ||
| CdS QDs; -1.2 V | IL-2 | 1.6 × 10-12 g/mL | 1.6 × 10-12-2.0 × 10-10 g/mL | ||
| 10 | Au @ BSA MSs-luminol; 0.32 V | 2,6-Sialylated glycans | 3.3 × 10-15 g/mL | 1.0 × 10-14-1.0 × 10-2 g/mL |
|
| TZZ; -1.8 V | 2,3-Sialylated glycans | 2.1 × 10-15 g/mL | 1.0 × 10-14-1.0 × 10-2 g/mL | ||
| 11 | Ru(bpy)32+; +1.2 V | AFP | 2.0 × 10-11 g/mL | - |
|
| Carbon nanodots; -1.2 V | CA153 | 5.0 × 10-3 U/mL | - | ||
| CA199 | 6.0 × 10-3 U/mL | - | |||
| CEA | 4.0 × 10-12 g/mL | - | |||
| 12 | Ru [phen]32+; +1.2 V | MCF-7 cancer cells | 15 | 1.0 × 102-1.0 × 106 cells/mL |
|
| Concanavalin A-conjugated AuNP-modified graphite-C3N4; -1.6 V | N-glycan expression | - | - | ||
|
| |||||
| ECL probe and onset potential | Target | LOD | Linear range | Ref. | |
| 13 | [dfppy)2Ir(dcbpy]PF6; +1.4 V | MMP-2 | 5.0 × 10-9 g/mL | 1.0 × 10-8-3.0 × 10-7 g/mL |
|
| [Ru [bpy]2 [mcbpy-O-Su-ester] [PF6]2; +0.9 V | MMP-7 | 1.0 × 10-11 g/mL | 5.0 × 10-11-1.0 × 10-9 g/mL | ||
| 14 | CIS@ZnS NCs; 0.10 V | PSA | - | - |
|
| [Ru [bpy]2 [dcbpy]]2+; 1.06 V | CA125 | - | - | ||
|
| |||||
| ECL probe and onset potential | Target | LOD | Linear range | Ref. | |
| 15 | CdS nanowires; - | Myo | 2.0 × 10-13 g/mL | 5.0 × 10-13-5.0 × 10-7 g/mL |
|
| RuSi@ Ru(bpy)32+ NPs; - | cTnI | 5.0 × 10-13 g/mL | 1.0 × 10-12 -1.0 × 10-7 g/mL | ||
| 16 | Luminol-AuNPs; - | Adenosine | 2.2 × 10-12 M | 5.0 × 10-12-5.0 × 10-9 M |
|
| ABEI-AuNPs: - | Thrombin | 1.2 × 10-14 M | 5.0 × 10-14 -5.0 × 10-10 M | ||
| 17 | Au@luminol; | MCF-7 cells | 20 | 1.0 × 102 -1.0 × 106 cells/mL |
|
| CdS QDs; | Mannose | - | 1.0 × 10-13-1.0 × 10-12 M | ||
| EGFR | - | 1.0 × 10-10-1.0 × 10-9 g/mL | |||